Read by QxMD icon Read


K Dwivedi, I S Prabhu, K M Bradley
Injectable cosmetic fillers are increasingly popular, but are not often considered as a cause of abnormal findings on imaging. We present a case of poly-L-lactic acid (PLLA) filler associated with 18-fluorodeoxyglucose (FDG) uptake, which had the potential to interfere with staging of a squamous cell carcinoma of the lateral tongue. We characterise the FDG-positron emission tomography/computed tomography (PET/CT) properties of a PLLA dermal filler, Sculptra® (Aventis), and highlight its potentially confounding appearance in the staging scans of oncological patients, particularly those with oral tumours...
February 2018: British Journal of Oral & Maxillofacial Surgery
Alfonso Vallejo, Angela A Garcia-Ruano, Carmen Pinilla, Michele Castellano, Esther Deleyto, Rosa Perez-Cano
BACKGROUND: The objective was to evaluate and compare safety and effectiveness of four different dermal fillers in the treatment of facial lipoatrophy secondary to Human Immunodeficiency Virus (HIV). METHODS: We conducted a clinical trial including 147 patients suffering from HIV-induced lipoatrophy treated with Sculptra® (poly-L-lactic acid), Radiesse® (calcium hydroxylapatite), Aquamid® (polyacrylamide) or autologous fat. Objective and subjective changes were evaluated during a 24-monthfollow-up...
November 8, 2017: Plastic and Reconstructive Surgery
Min-Woo Kim, Hyun-Sun Park, Hyun-Sun Yoon, Soyun Cho
Injectable poly-L-lactic acid (PLLA) is world-famous filler used in lipoatrophy and facial rejuvenation because of its collagen neogenesis effect which leads to gradual volume restoration. Until recently, quite a number of unwanted adverse events of PLLA have been reported. However, to the best of our knowledge, paraffinoma as a complication of PLLA has never been reported. We herein describe the first case of paraffinoma after Sculptra® injection and propose its possible mechanism.
December 2016: Annals of Dermatology
Z Paul Lorenc, Thomas Greene, Ronald W Gottschalk
A survey of Sculptra<sup>®</sup> Aesthetic injectors was conducted to understand how the product is being currently reconstituted and injected. Questions were asked of injectors to understand their reasons for choice and volume of diluent(s), additions, and time for the reconstitution process. These results are discussed in the context of the past history of the product over the last decade, with a focus on adverse events such as papules and nodules. <br /><br /> <em>J Drugs Dermatol...
June 1, 2016: Journal of Drugs in Dermatology: JDD
Connie Brennan
Treatment guidelines are a crucial part of every medical aesthetic practice and must be in place before utilizing aesthetic medical injectables. An "Aesthetic Policy and Procedure Manual" features specific details (e.g., patient assessment, indication, contraindications, warnings and precautions, injection techniques, documentation, etc.) around dermal fillers (e.g., Restylane, Juvéderm, Voluma), hyaluronidase, neurotoxins (e.g., Botox Cosmetic, Dysport, and Xeomin) and Sculptra. This article describes why an "Aesthetic Policy and Procedure" manual is a necessary tool in every aesthetic provider's armamentarium, what it is composed of, as well as how these guidelines serve as a protective mechanism for the aesthetic provider's clinic if legal action is brought against their staff, their medical director, and/or their clinic...
July 2015: Plastic Surgical Nursing
Ivan Vrcek, Tarek El-Sawy, Eva Chou, Theresa Allen, Tanuj Nakra
Injectable fillers have become a prevalent means of facial rejuvenation and volume expansion. While typically well tolerated, serious complications have been reported. The authors present a case in which an otherwise healthy female with a history of multiple filler injections including poly-L-lactic acid, developed 3 weeks of neuropathic pain in the left temporal fossa following injection. To the best of the authors knowledge, neuropathic pain has not been reported as a complication following poly-L-lactic acid injection...
May 2017: Ophthalmic Plastic and Reconstructive Surgery
Richard Swift
No abstract text is available yet for this article.
September 2015: Plastic and Reconstructive Surgery
Redaelli Alessio, Berthold Rzany, Linda Eve, Yann Grangier, Pedro Herranz, Frédérique Olivier-Masveyraud, Danny Vleggaar
Over the last few years, there have been a number of important changes in how we appreciate and understand the aging face. Volume loss is now recognized as a major component of facial aging. Treatment options that replace lost volume are increasingly used for recontouring and rejuvenation of the aging face. In this review we present and discuss the European Expert Group recommendations on the ideal use of the unique collagen stimulator, poly-L-lactic acid (PLLA, Sculptra®, Sinclair Pharmaceuticals) for facial rejuvenation lasting up to 25 months...
September 2014: Journal of Drugs in Dermatology: JDD
Daniel P Friedmann, Sabrina G Fabi, Mitchel P Goldman
INTRODUCTION: Facial aging is a gradual process that involves a complex interaction of multiple factors including cutaneous photodamage and laxity, subcutaneous tissue volume loss, and bony resorption. These features have all been show to significantly improve with intense pulsed light (IPL), microfocused ultrasound (MFUS, Ultherapy), and poly-L-lactic acid (PLLA). METHODS: To review the use of IPL, MFUS, and PLLA in combination with the treatment of facial aging...
June 2014: Journal of Cosmetic Dermatology
Melanie Palm, Pamela Chayavichitsilp
Poly-L-lactic acid (PLLA) is a biostimulatory agent that can correct bony and soft tissue facial deficiencies by producing gradual volume restoration. Proper patient selection and clear expectations are important to treatment success. Correct product preparation, injection technique, and patient follow-up correlates with increased patient safety, outcomes, and satisfaction. Alone, or in combination with other rejuvenative procedures, Sculptra® provides longer-lasting improvement to signs of facial aging.
September 2012: Journal of Drugs in Dermatology: JDD
Elizabeth Guardiani, Steven P Davison
No abstract text is available yet for this article.
January 2012: Plastic and Reconstructive Surgery
Lisa Nelson, Kenneth J Stewart
UNLABELLED: HIV lipoatrophy is a stigmatizing condition associated with significant psychological morbidity. The aim of this study was to evaluate change in facial volume and psychological morbidity following treatment with autologous fat, Sculptra and Bio-alcamid. METHODS: HIV LD patients were treated based on a clinical assessment in a prospective, observational study. 3-D images were obtained pre-operatively then at 2, 6 and 12 months post-operatively using the DI3D system...
April 2012: Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS
Clark Friedrich Schierle, Laurie A Casas
BACKGROUND: Characteristics of the aging face include soft tissue atrophy, loss of skin elasticity resulting in excess facial skin, and gravitational descent or ptosis of facial soft tissues. Poly-L-lactic acid (PLLA) is a synthetic biodegradable polymer that provides soft tissue augmentation through stimulation of an inflammatory tissue response with subsequent collagen deposition. OBJECTIVE: The authors discuss the special considerations inherent in facial aging, describe the mechanism of action and indications for a new PLLA filler under consideration for Food and Drug Administration (FDA) approval (Sculptra Aesthetic, sanofi-aventis US, Bridgewater, New Jersey), and detail the results of a two-year off-label pilot study with the product...
January 2011: Aesthetic Surgery Journal
F Olivier Masveyraud
AIM OF THE STUDY: Patients seeking care of facial ageing demand an aesthetic result that appears natural and is very safe, with techniques the less invasive possible. Our series of cases helps analyse the efficiency and safety of L-polylactic acid in the management of facial ageing. PATIENTS AND METHOD: Retrospective analysis of a single series of patients treated with L-polylactic acid (Sculptra™) between September 2000 and September 2007. All patients over 18 years, consulting for facial ageing and/or loss of volume and treated with L-polylactic acid injections, were included in our evaluation...
April 2011: Annales de Chirurgie Plastique et Esthétique
Tiffani K Hamilton, Cheryl M Burgess
With demand for minimally invasive cosmetic procedures rising in patients of color, it is becoming increasingly important for clinical dermatologists to be aware of specific needs of these patients. This article therefore reviews considerations for using cosmetic procedures on skin of color, and reports the authors' clinical experience with the use of injectable poly-L-lactic acid (PLLA, Sculptra, Dermik Laboratories, a business of sanofi-aventis U.S. LLC) in this patient population. The authors' experience indicates that patients with skin of color may require an increased interval between treatments; however, with proper attention to patient selection and administration technique, injectable PLLA can be used effectively in this patient group...
May 2010: Journal of Drugs in Dermatology: JDD
Rebecca Fitzgerald, Danny Vleggaar
Sculptra (Sanofi-Aventis, Bridgewater, NJ) was approved by the U.S. Food Drug Administration (FDA) for use in HIV-related lipoatrophy in 2004 and received FDA approval for cosmetic use as Sculptra Aesthetic in July 2009. The authors have experience with this product in both applications. The purpose of this article is to share their methodology. Both soft-tissue and supraperiosteal injections will be illustrated and discussed in detail. Much progress has been made in the last decade in understanding of volume changes in all structural layers of the face, and this will be briefly reviewed as it is pertinent to the methodology...
October 2009: Journal of Drugs in Dermatology: JDD
Victor Lacombe
Sculptra is a biocompatible, resorbable injectable filler composed of poly-L-lactic acid (PLLA). It falls in the class of a stimulatory filler that creates its effect through encouraging neocollagenesis when injected. As it differs from traditional, static fillers such as hyaluronic acid and collagen, it requires a special understanding of how it works, where it can be used, and how it should be injected. The goal of this article is to review the nature of stimulatory volume replacement with a focus on PLLA and its unique considerations...
May 2009: Facial Plastic Surgery: FPS
Neil S Sadick, Laura Palmisano
This report describes a novel use of injectable poly-L-lactic acid (PLLA; Sculptra) for the correction of acne scars in an adult patient. The patient, a 60-year-old white woman, had previously been treated for acne scars with CO(2) laser resurfacing, dermabrasion and trichloroacetic acid peels, as well as collagen, calcium hydroxylapatite and hyaluronic acid dermal fillers. These treatment approaches did not provide satisfactory improvement of the patient's acne scars. The latest course of therapy consisted of seven treatment sessions during which injectable PLLA was administered serially into individual scars and depressions in the patient's nasolabial folds, mid-cheeks and chin...
2009: Journal of Dermatological Treatment
Miles Graivier
BACKGROUND: Deep lines, facial folds, retracted scars, and contour depressions on all areas of the body have typically been resistant to efforts at release. OBJECTIVE: A method using a wire dissector to achieve complete release or subcision of these subdermal attachments with access only through the needle insertion sites is described. METHODS: The wire dissector was inserted into the subcutaneous tissue just below the dermal-subcutaneous tissue junction and brought out of the skin on one side of the defect...
July 2006: Aesthetic Surgery Journal
Ronald L Moy, Edgar F Fincher
Sculptra (poly-L-lactic acid), a new injectable soft tissue filler designed to stimulate neocollagenesis, increase dermal thickness, and enhance volume, is most commonly used for the midface and temporal fossa, with more limited use in the mental and prejowl areas. In the authors' practice, Sculptra injections have virtually replaced autologous fat transfer, yielding excellent results for patients with mild to moderate midface and jowl laxity.
November 2005: Aesthetic Surgery Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"